Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Why Is Indaptus Therapeutics (INDP) Stock Up +8.52% Today?

Why Is Indaptus Therapeutics (INDP) Stock Up +8.52% Today?

Key Takeaways

  • INDP shares were up 8.52% at $3.44 in Monday afternoon trading, versus the prior close of $3.17, with an intraday range of $3.095–$3.550.
  • The primary catalyst was the first full trading session following Indaptus Therapeutics' third-quarter results and corporate update, released after Friday's closing bell.
  • Secondary drivers included a narrowed quarterly loss of $1.05 million, roughly $30.6 million of cash and short-term investments, and management's explicit reference to a possible future FDA submission path for an exploratory sleep-related neurotechnology device.
  • Broader context was hostile: the small-cap biotech complex and mega-cap technology both sold off sharply, making the move a clear divergence from sector direction.
  • Volume was running modestly above the recent 20-day average but far below the levels seen during September's surge.
  • News Significance Score: 25/100 — routine quarterly update, with a price move roughly in line with the stock's own volatile norm.
  • The stock remains above its 50-day and 200-day moving averages, though the $3.55 intraday high marked a fresh short-term resistance test.
  • Traders are watching whether the advance holds into the close, any follow-through on strategic alternatives language, and the eventual release of placement shares.
  • Deeper detail on Price Targets, Earnings, and Forecast data is available on the dedicated pages.
  • Readers can also review Trending AI Robots for automated strategies built around stocks like this one.

Opening Summary

Indaptus Therapeutics, Inc. (INDP) is a New York-based, pre-revenue biotechnology company built around its patented Decoy platform, which uses attenuated, killed non-pathogenic Gram-negative bacteria designed to activate innate and adaptive immunity. The company has wound down clinical activity for its lead candidate Decoy20 and is now pursuing a strategic review alongside early-stage research into a potential neurotechnology and neural-network-based device for sleep-related conditions.

Shares rose 8.52% to $3.44 in Monday trading, up from Friday's close of $3.17 — a gain of $0.27. The direction was unambiguously higher, driven by delayed buying interest in the third-quarter report and corporate update issued after Friday's close, which gave the market its first uninterrupted session to price the news.

Third-Quarter Update Finally Gets a Full Session

Indaptus disclosed third-quarter results after the bell on Friday, and the initial after-hours response was muted, with the stock quoted up less than 2%. Monday's session told a different story. Buyers pushed the shares from a flat open to $3.55 before midday, a pattern consistent with retail and momentum accounts digesting the release during regular hours rather than in thin evening quotes.

The numbers themselves were modest but constructive. The quarterly net loss narrowed to approximately $1.05 million from roughly $2.98 million a year earlier, breakeven on a per-share basis at a loss of $0.01. Research and development expense fell 82% to about $0.27 million, and general and administrative costs declined 24%. Total liquidity of roughly $30.6 million, including certificates of deposit redeemable on demand plus the remaining proceeds of a September private placement, gives management an unusually long runway for a company of this size.

Strategic Review and Sleep-Technology Language

The more speculative driver was the wording of the corporate update. Indaptus said it continues to evaluate the Decoy platform and existing therapeutic assets for licensing, partnership and other strategic opportunities, and repeated that it is considering investments in or acquisitions of operating businesses. It also described early-stage, preclinical evaluation of a sleep-focused neurotechnology device, with the stated ambition of exploring a possible development pathway toward a future FDA submission.

That combination — a funded shell with a strategic-review mandate — is precisely what has driven this stock's extraordinary 2026 run from under $1 in August to above $3.50. Today's move extends that narrative without introducing a new, concrete transaction.

Market Context and Trading Activity

The advance stood out because the backdrop was decisively negative. The S&P 500 fell about 2.0%, the Nasdaq-100 proxy QQQ dropped roughly 2.65%, and biotech benchmarks were weaker still, with the XBI down 2.7% and the IBB off 1.8%. A micro-cap rallying more than 8% into that tape signals stock-specific demand rather than sector sympathy.

Volume was elevated relative to the quiet recent baseline — roughly 300,000 shares by mid-afternoon against a 20-day average near 239,000 — but dwarfed by the millions of shares that traded in September. The float remains small at about 45 million shares with insider ownership near 70%, which amplifies price swings. The stock is holding above its 50-day average near $2.96 and its 200-day average near $2.32, and RSI has moved from neutral territory toward the low 60s.

News Significance Score

The scoring scale runs from 0, meaning no meaningful news and a price move that is normal for the stock, to 100, meaning transformative news and an extreme, rare move. Indaptus scores 25 out of 100.

The verified news was a routine quarterly report for a pre-revenue company: no revenue, no active clinical programs, and cost reductions that were partly telegraphed in prior quarters. It was constructive but not material relative to a market capitalization near $460 million. The price move was equally unremarkable by this stock's standards — 8.52% is roughly in line with the typical absolute daily move of about 8.6%, and 19 of the last 60 sessions produced moves of equal or larger size. With both components weak, the two combine into a low score.

What Comes Next for INDP

Indaptus has no scheduled earnings release until its fourth-quarter and full-year 2026 report, expected in the first quarter of 2027, so the near-term calendar is driven by corporate announcements rather than financial reporting. Investors will focus on whether the strategic review produces a concrete licensing deal, partnership, or acquisition, and on any further detail about the sleep-device research program.

The principal risk is dilution: 153.6 million shares are now outstanding following the October 16 closing of the September placement, and the company has repeatedly acknowledged the need for additional capital. Nasdaq continued-listing requirements and the absence of an active clinical program remain structural overhangs. Analyst coverage is thin, with a single firm carrying a buy rating. Sentiment in the broader small-cap biotech complex, which weakened again today, will likely determine whether this divergence holds.

Trending AI Robots

Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in its curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the featured lineup rotates as conditions change. For investors navigating volatile micro-caps like this one, reviewing the current leaders can help frame how automated strategies are positioning right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: INDP

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


INDP saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for INDP moved out of overbought territory on November 19, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 41 similar instances where the indicator exited the overbought zone. In 38 of the 41 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INDP as a result. In 87 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for INDP turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 44 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INDP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

Bullish Trend Analysis

The 50-day moving average for INDP moved above the 200-day moving average on October 22, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +9.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where INDP advanced for three days, in 170 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

INDP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 66 of 90 cases where INDP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. INDP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (38.898) is normal, around the industry mean (3.596). P/E Ratio (-0.933) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INDP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -7%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -25%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
3 Columbus Circle 15th Floor
Phone
+1 646 427-2727
Employees
5
Web
https://www.indaptusrx.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.